Saskatchewan expands Cystic Fibrosis drug coverage with new treatment option
The province of Saskatchewan has expanded its public drug coverage to include Alyftrek, a treatment for patients aged six and older with cystic fibrosis. This move follows federal recommendations and pricing negotiations, increasing the number of available therapies for the disease in the region.
Why it matters
Expanding access to specialized medication significantly improves quality of life and health outcomes for patients with rare genetic conditions.
People living with cystic fibrosis in Saskatchewan now have access to an additional treatment option as the province begins covering the cost of a new medication.
Starting Aug. 1, coverage for Alyftrek is available to cystic fibrosis patients aged six and older who meet specific medical criteria. The medication is designed for patients with one of 266 rare genetic mutations that cause cystic fibrosis.
Health Minister Jeremy Cockrill said the expanded coverage will provide more treatment options for people living with the disease.
“Our government is pleased to cover the cost of this new treatment for Saskatchewan patients with cystic fibrosis,” Cockrill said. “Alyftrek has been shown to improve quality of life in patients with CF, so expanding coverage puts CF patients first by helping them to lead healthier lives.”
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in